Triple Negative Metastatic Breast Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

In contrast to HER2 overexpression or gene amplification, triple-negative breast cancer (TNBC) lacks the overexpression of the estrogen and progesterone receptors. It accounts for 10-15% of breast cancer cases and has the worst prognosis. TNBC is overrepresented in premenopausal Black women and is linked to significant psychological and treatment burden, as well as economic toxicity. In the United States, triple-negative breast cancer was diagnosed in 12% of cases between 2012 and 2016, and its 5-year survival rate was 8% to 16% lower than that of hormone receptor-positive cancer. The demographics of less deadly luminal cancers are still being taken into account when developing prevention and screening strategies. We now have a better understanding of the molecular heterogeneity of TNBC as a result of recent efforts to characterize TNBC tumors using analyses of the genomic, transcriptomic, and immune microenvironment. Sequential single-agent chemotherapy has been the go-to therapy for TNBC because it lacks a clear molecular target.

Description

Under expression of the estrogen and progesterone receptors, as well as the absence of HER2 overexpression or gene amplification, are characteristics of triple-negative breast cancer (TNBC). The prognosis is the worst, and it accounts for 10-15% of breast cancer cases. TNBC is overrepresented in Black and premenopausal women and is linked to significant psychological and treatment burden, as well as economic toxicity. Biologically heterogeneous and associated with a variety of clinical and epidemiological behaviours, TNBC shares these characteristics with other breast cancers. However, unlike other clinical subtypes, TNBC is still without tumor-specific targeted therapies. Early outcomes in TNBC have improved as a result of developments in multiplex chemotherapy and intensive care, including the addition of immunotherapy. Patients with BRCA1 mutations are more likely to develop metastatic TNBC, so all patients with TNBC younger than 60 years old should be tested for BRCA mutations. Patients with a history of TNBC and active metastatic disease should undergo a second biopsy because, in up to 5% of cases, the hormone receptor status of the primary tumor and metastatic disease may differ. The median overall survival following treatment was 13.3 months. For patients with metastatic TNBC, the current standard of care is to continue chemotherapy until the disease progresses; however, the ideal chemotherapy regimen has not yet been identified. Breast tumor subtypes that have different molecular and cellular origins and clinical behaviours collectively fall under the umbrella term of breast cancer. Breast cancer is the most prevalent cancer among women that is fatal and the main reason women die from cancer globally. Compared to other types of breast cancer, early-stage triple-negative breast cancer is more likely to spread to other organ systems. In fact, one study discovered that metastases were four times more likely to form in people with early-stage TNBC.

Triple Negative Metastatic Breast Cancer (Epidemiology)

From 2012 to 2016, triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United States, and the 5-year survival rate was 8% to 16% lower than for hormone receptor-positive disease. However, prevention and screening strategies are still being adapted to the demographics of less lethal luminal cancers. Triple-negative cancer disproportionately affects African-American women and carriers of germline mutations in BRCA and PALB2. African Americans with triple-negative breast cancer were nearly twice as likely to die from the disease, even after controlling for treatment delay, stage, and socioeconomic factors. Overall, the incidence of breast cancer increased with age, from 1.5 per 100,000 women aged 20 to 24 years to 421.3 per 100,000 women aged 75 to 79 years; 95% of new cases occur in women aged 40 and over. The average age of women at the time of breast cancer diagnosis was 63 years. From 2005 to 2014, the incidence of breast cancer in women over the age of 50 remained relatively stable. In contrast, the infection rate among women under the age of 50 has increased by 0.2% per year since the mid-1990s. In the United States, non-Hispanic whites have a higher rate of breast cancer than women of other races and ethnicities. African Americans are overrepresented among women under 40. In addition, more African American women were diagnosed with larger advanced tumors (>5 cm) and had an increased risk of dying from breast cancer at all ages. The incidence of localized breast cancer in women aged 50 and over stabilized in the late 1990s; this is consistent with the proposed test saturation effect. However, the incidence of breast cancer in situ in young women continues to increase.

Triple Negative Metastatic Breast Cancer -Current Market Size & Forecast Trends

The market for triple-negative metastatic breast cancer (TNBC) treatment in the G8 countries, including the U.S., EU4 (France, Germany, Italy, Spain), the UK, Japan, and China, is projected to grow significantly. In 2024, the market is estimated to be valued at approximately USD 670.5 million, with expectations to reach around USD 1.04 billion by 2034, reflecting a compound annual growth rate (CAGR) of 4.6%. The U.S. is expected to dominate this market, accounting for about 39.6% of the global share in 2022, driven by increasing incidence rates and advancements in treatment options. Notably, China is emerging as a key player, holding an 11% market share due to rising cases of TNBC and the influence of traditional medicine. As awareness and healthcare infrastructure improve across these regions, the TNBC treatment market is well-positioned for substantial growth through 2035.

We now have a better understanding of the molecular heterogeneity of TNBC as a result of recent efforts to characterize TNBC tumors using analyses of the genomic, transcriptomic, and immune microenvironment. Sequential single-agent chemotherapy has been the usual treatment for TNBC because it lacks a clear molecular target. The mainstay of care for metastatic TNBC is still chemotherapy. The triple negative paradox refers to the fact that TNBC is naturally chemosensitive but is also prone to quick relapse and drug resistance. For BRCA1/BRCA2 wild-type patients who do not receive these agents in a neoadjuvant or adjuvant manner, the majority of guidelines suggest an anthracycline- or wild-type taxane-based regimen. The majority of patients with metastatic TNBC (mTNBC) continue to be treated with cytotoxic chemotherapy, but the time to response is frequently brief and the median overall survival is only 12-18 months. To improve the prognosis of these patients, it is crucial to find new therapeutic approaches. However, recent research has indicated that new targeted therapies can help TNBC patients achieve better results. According to new clinical trial findings, combining chemotherapy with the immunotherapy drug pembrolizumab (Keytruda) may extend the survival time of patients with advanced triple-negative breast cancer. Trodelvy (sacituzumab govitecan-hziy) recently received accelerated approval from the US Food and Drug Administration to treat adults with triple-negative breast cancer that has spread to other body parts. Prior to receiving Trodelvy, patients must undergo at least two treatments.

Report Highlights

Triple Negative Metastatic Breast Cancer - Current Market Trends

Triple Negative Metastatic Breast Cancer - Current & Forecasted Cases across the G8 Countries

Triple Negative Metastatic Breast Cancer - Market Opportunities and Sales Potential for Agents

Triple Negative Metastatic Breast Cancer - Patient-based Market Forecast to 2035

Triple Negative Metastatic Breast Cancer - Untapped Business Opportunities

Triple Negative Metastatic Breast Cancer - Product Positioning Vis-a-vis Competitors' Products

Triple Negative Metastatic Breast Cancer - KOLs Insight